Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bezoar Antipyrotic Tablet
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bezoar Antipyrotic Tablet is a Traditional Chinese Medicine (TCM) formulated as a tablet. It is primarily used for its antipyretic (fever-reducing) and anti-inflammatory properties, and has also demonstrated anti-bacterial functions against certain pathogens, including drug-resistant Staphylococcus aureus. The drug contains bezoar (Calculus Bovis) and is likely composed of other traditional Chinese herbal ingredients. It is a product marketed by Yantai Tianzheng Pharmaceutical Co., Ltd., which was acquired by Bohai Pharmaceuticals Group, Inc.
- Other names
- Bezoar Antipyretic Tablets
Beyond the preview
Go deeper on Bezoar Antipyrotic Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bezoar Antipyrotic Tablet.